Latest / The BioHub - by Avetix
Episode 102 - Miquel Vila-Perello - CEO of SpliceBio
We recently sat down with Miquel Vila-Perello, CEO of SpliceBio, at Jefferies - during which the team picked up the Series B Raise of the Year at the 2025 ELAs for their $135million round earlier this year.
SpliceBio are a Barcelona-based gene therapy company using a proprietary Protein Splicing platform to address diseases caused by large genes that traditional AAV vectors can’t deliver. Their lead program, SB-007 for Stargardt disease, is currently being investigated in their Phase 1/2 ASTRA study, marking a key clinical milestone in a condition with no approved treatments.
It was great to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.